Acadia Pharmaceuticals is nearly double, erasing its lows made earlier this year. Thanks to getting the green light from the FDA’s Ad Comm for its Nuplazid product, the stock is on the mend. Nuplazid has an advantage in the US market. It is a small player in the region. Although the costs for treating patients with PD Psychosis is high, Nuplazid is a justifiable drug for treatment due to its cost-effectiveness. ACAD may play to the advantages of operating in a small market. Cost recovery for drug recovery is achievable by passing the costs to the patients. Classified as an antipsychotic, it is in the protect class, which means patients get coverage. The risk is that if patients are elderly or on limited income, sales will disappoint if government does not support the high costs. Free: More hot biotech ideas: Will Relypsa Survive?Intrexon (XON) Could Trade to $30Why Bankruptcy is Not Happening for Valeant